67 related articles for article (PubMed ID: 38443927)
1. ZNF384 transcriptionally activated MGST1 to confer TMZ resistance of glioma cells by negatively regulating ferroptosis.
Yan T; Hu P; Lv S; Ye M; Wu M; Fang H; Xiao B
Cancer Chemother Pharmacol; 2024 Jun; ():. PubMed ID: 38824270
[TBL] [Abstract][Full Text] [Related]
2. Glioma-targeted oxaliplatin/ferritin clathrate reversing the immunosuppressive microenvironment through hijacking Fe
Li X; Cheng Y; Yang Z; Ji Q; Huan M; Ye W; Liu M; Zhang B; Liu D; Zhou S
J Nanobiotechnology; 2024 Mar; 22(1):93. PubMed ID: 38443927
[TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin disrupts pathological features of glioma cells and associated macrophages independent of apoptosis induction.
Roberts NB; Alqazzaz A; Hwang JR; Qi X; Keegan AD; Kim AJ; Winkles JA; Woodworth GF
J Neurooncol; 2018 Dec; 140(3):497-507. PubMed ID: 30132163
[TBL] [Abstract][Full Text] [Related]
4. Oroxylin A reversed Fibronectin-induced glioma insensitivity to Temozolomide by suppressing IP
Ding Y; Zhou Y; Li Z; Zhang H; Yang Y; Qin H; Xu Q; Zhao L
Life Sci; 2020 Nov; 260():118411. PubMed ID: 32918978
[TBL] [Abstract][Full Text] [Related]
5. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
[TBL] [Abstract][Full Text] [Related]
6. Nano-Codelivery of Temozolomide and siPD-L1 to Reprogram the Drug-Resistant and Immunosuppressive Microenvironment in Orthotopic Glioblastoma.
Liu D; Cheng Y; Qiao S; Liu M; Ji Q; Zhang BL; Mei QB; Zhou S
ACS Nano; 2022 May; 16(5):7409-7427. PubMed ID: 35549164
[TBL] [Abstract][Full Text] [Related]
7. Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma.
Ding C; Yi X; Chen X; Wu Z; You H; Chen X; Zhang G; Sun Y; Bu X; Wu X; Lin Z; Gu J; Lin Y; Kang D
J Exp Clin Cancer Res; 2021 May; 40(1):164. PubMed ID: 33975615
[TBL] [Abstract][Full Text] [Related]
8. Immuno markers in newly diagnosed glioblastoma patients underwent Stupp protocol after neurosurgery: a retrospective series.
Gurrieri L; Mercatali L; Ibrahim T; Fausti V; Dall'Agata M; Riva N; Ranallo N; Pasini G; Tazzari M; Foca F; Bartolini D; Riccioni L; Cavatorta C; Morigi FP; Bulgarelli J; Cocchi C; Ghini V; Tosatto L; Martinelli G; Pession A; Ridolfi L
J Neurooncol; 2023 Aug; 164(1):55-64. PubMed ID: 37584750
[TBL] [Abstract][Full Text] [Related]
9. Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment.
Yang M; Qin C; Tao L; Cheng G; Li J; Lv F; Yang N; Xing Z; Chu X; Han X; Huo M; Yin L
Biomaterials; 2023 Oct; 301():122253. PubMed ID: 37536040
[TBL] [Abstract][Full Text] [Related]
10. Close the cancer-immunity cycle by integrating lipid nanoparticle-mRNA formulations and dendritic cell therapy.
Zhang Y; Hou X; Du S; Xue Y; Yan J; Kang DD; Zhong Y; Wang C; Deng B; McComb DW; Dong Y
Nat Nanotechnol; 2023 Nov; 18(11):1364-1374. PubMed ID: 37500773
[TBL] [Abstract][Full Text] [Related]
11. Autophagy mediates an amplification loop during ferroptosis.
Lee S; Hwang N; Seok BG; Lee S; Lee SJ; Chung SW
Cell Death Dis; 2023 Jul; 14(7):464. PubMed ID: 37491375
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of phosphoglycerate dehydrogenase induces ferroptosis and overcomes enzalutamide resistance in castration-resistant prostate cancer cells.
Wang J; Zeng L; Wu N; Liang Y; Jin J; Fan M; Lai X; Chen ZS; Pan Y; Zeng F; Deng F
Drug Resist Updat; 2023 Sep; 70():100985. PubMed ID: 37423117
[TBL] [Abstract][Full Text] [Related]
13. Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment.
Iturrioz-Rodríguez N; Sampron N; Matheu A
Theranostics; 2023; 13(9):2734-2756. PubMed ID: 37284445
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
